Breaking News Instant updates and real-time market news.

GS

Goldman Sachs

$242.38

-0.51 (-0.21%)

, YHOO

Tag AABA

$41.34

0.11 (0.27%)

12:29
01/10/17
01/10
12:29
01/10/17
12:29

On The Fly: Top stock stories at midday

Stocks began the session mixed, with the Dow struggling following a downgrade of Goldman Sachs (GS) to Sell by Citigroup prior to the open. The Nasdaq was the leader all morning, but the Dow and S&P chipped away at their losses and eventually made it into positive territory. The rebound has pushed the Dow back to within 50 points of its elusive 20,000 level ahead of the start of the earnings season, which will kick off with reports this Friday from JPMorgan (JPM) and Wells Fargo (WFC). ECONOMIC NEWS: In the U.S., the NFIB gauge of small business optimism rose 7.4 points in December to a 12-year high of 105.8. The JOLTS report showed job openings rose 71,000 to 5.5M in November. Wholesale inventories bounced 1.0% in November, with sales up 0.4%. In Asia, China's consumer price index rose 2.1% in December, while the producer price index rose 5.5% last month, continuing the inflationary upswing that began in September. COMPANY NEWS: Shares of Yahoo (YHOO) gained about 2% near noon after the company announced that it will change its name to "Altaba" once the sale of its core internet business to Verizon (VZ) is concluded. Among the company's remaining assets will be Yahoo's stake in Alibaba (BABA) and Yahoo Japan. Additionally, Yahoo said that several longtime directors, including CEO Marissa Mayer, will step down following the completion of the deal... Shares of Valeant Pharmaceuticals (VRX) have advanced almost 6% after the drugmaker agreed to sell its CeraVe, AcneFree and AMBI skincare brands to L'Oreal (LRLCY) for $1.3B in cash and to divest Dendreon to Sanpower Group for about $820M... Meanwhile, Barracuda Networks' (CUDA) stock rose about 2% after the security systems provider reported better than expected quarterly results, as companies move more and more to the cloud. MAJOR MOVERS: Among the notable gainers was Illumina (ILMN), which advanced over 16% after analysts responded positively to the company's unveiling of the NovaSeq Series, a new and scalable sequencing architecture "expected one day to enable a $100 genome." Also higher was Sarepta Therapeutics (SRPT), which gained about 20% after the company disclosed sales data for the launch of its Duchenne muscular dystrophy drug Exondys 51. Additionally, Del Frisco's (DFRG) rose almost 10% after reporting preliminary fourth quarter revenue and 2016 guidance. Among the noteworthy losers was Ascena Retail (ASNA), which slid about 5% after cutting its fiscal 2017 and fourth quarter earnings per share guidance as well as reporting a November/December same-store sales decline. Also lower was Williams Companies (WMB), which fell almost 10% after the company and Williams Partners (WPZ) announced a financial repositioning under which Williams will forfeit payments for a larger stake in the partnership. Additionally, Williams announced a 65M share secondary offering priced at $29.00, while Jefferies analyst Christopher Sighinolfi downgraded the stock to Hold from Buy. Also lower was WD-40 (WDFC), which dropped about 8% after the company reported worse than expected first quarter results. INDEXES: Near midday, the Dow was up 61.61, or 0.31%, to 19,948.99, the Nasdaq was up 28.24, or 0.51%, to 5,560.06, and the S&P 500 was up 9.34, or 0.41%, to 2,278.24.

GS

Goldman Sachs

$242.38

-0.51 (-0.21%)

YHOO

Tag AABA

$41.34

0.11 (0.27%)

VZ

Verizon

$53.09

0.405 (0.77%)

BABA

Alibaba

$97.46

2.74 (2.89%)

VRX

Valeant

$16.27

0.919 (5.99%)

LRLCY

L'Oreal

$36.22

0.395 (1.10%)

CUDA

Barracuda

$24.36

0.59 (2.48%)

ILMN

Illumina

$141.54

0.05 (0.04%)

SRPT

Sarepta

$31.26

1.18 (3.92%)

DFRG

Del Frisco's

$15.85

-0.15 (-0.94%)

ASNA

Ascena Retail

$6.01

0.01 (0.17%)

WMB

Williams

$28.85

-3.085 (-9.66%)

WPZ

Williams Partners

$38.64

-0.025 (-0.06%)

WDFC

WD-40

$117.30

-1.95 (-1.64%)

  • 10

    Jan

  • 10

    Jan

  • 10

    Jan

  • 10

    Jan

  • 18

    Jan

  • 24

    Jan

  • 16

    Feb

GS Goldman Sachs
$242.38

-0.51 (-0.21%)

01/10/17
01/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Moody's (MCO) was downgraded to Equal Weight from Overweight at Barclays and to Neutral from Buy at UBS. 2. Goldman Sachs (GS) and Comerica (CMA) were downgraded to Sell from Neutral at Citi. 3. T-Mobile (TMUS) downgraded to Neutral from Buy at MoffettNathanson. 4. AMAG Pharmaceuticals (AMAG) downgraded to Market Perform from Outperform at Leerink and to Neutral from Buy at Janney Capital. 5. BP (BP) downgraded to Market Perform from Outperform at BMO Capital analyst Brendan Warn citing his belief that the company will make a major acquisition this year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/17
SBSH
01/10/17
DOWNGRADE
Target $225
SBSH
Sell
Goldman Sachs downgraded to Sell from Neutral at Citi
Citi analyst Keith Horowitz downgraded Goldman Sachs (GS) to Sell with a $225 price target, representing 6% downside from current levels. While higher interest rates benefit fixed income trading, the path is "relatively uncertain and the bar is relatively high" for Goldman, Horowitz tells investors in a research note. The analyst believes U.S. bank stocks do not offer compelling risk/reward profiles following the recent rally. Horowitz this morning also downgraded Comerica (CMA) to Sell while keeping Buy ratings on Wells Fargo (WFC) and Bank of America (BAC).
01/06/17
UBSW
01/06/17
NO CHANGE
Target $285
UBSW
Buy
Goldman Sachs price target raised to $285 from $234 at UBS
UBS analyst Brennan Hawken raised his price target on Goldman Sachs $285 from $234 citing its earnings power and expectations for the bank to take market share as the revenue environment improves. Hawken reiterated his Buy rating on Goldman Sachs shares.
12/21/16
12/21/16
DOWNGRADE
Target $240

Neutral
Goldman Sachs downgraded due to valuation at Atlantic Equities
As previously reported, Atlantic Equities downgraded Goldman Sachs to Neutral from Overweight. Analyst Christopher Wheeler said Goldman will be a major beneficiary of a better tone to capital markets post-election but said shares have rallied strongly through his $240 price target.
YHOO Tag AABA
$41.34

0.11 (0.27%)

01/05/17
RHCO
01/05/17
NO CHANGE
RHCO
Verizon likely to proceed with Yahoo acquisition, says SunTrust
After Bloomberg reported that Verizon (VZ) was seeking a $5.5B loan, SunTrust analyst Kunal Madhukar says that, assuming the report is accurate, the loan would probably be used to finance Verizon's takeover of Yahoo's (YHOO) core business. The analyst says that if the report is accurate, the deal will probably proceed. Madhukar keeps a Hold rating on Yahoo.
10/28/16
OPCO
10/28/16
NO CHANGE
Target $1000
OPCO
Outperform
Alphabet price target raised to $1000 from $970 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for Alphabet (GOOG) to $1000 from $970 following "strong" Q3 results. The analyst believes Alphabet continues to benefit from the same trends, namely demand for mobile clicks driven by improved ad formats, YouTube ads and shift to programmatic. Further, he sees Google Cloud as the fastest growing unit, and expects increased investor focus in 2017. Meanwhile, Helfstein sees no material signs of share loss to Facebook (FB), with Alphabet gaining from Yahoo (YHOO)/Microsoft (MSFT) and other search players. The analyst reiterates an Outperform rating on Alphabet's shares.
10/25/16
OPCO
10/25/16
NO CHANGE
Target $970
OPCO
Outperform
Oppenheimer remains bullish on Alphabet ahead of earnings
Oppenheimer analyst Jason Helfstein remains bullish on Alphabet (GOOG; GOOGL) ahead of its Q3 earnings release. However, the analyst sees more headwinds than in the Q2 as agency holding company results suggest a slowdown in large-company ad spending on U.S. presidential/political in U.S./Europe. On the positive side, Helfstein says U.S. retail sales remains healthy and YouTube usage remains strong. Furthermore, he expects moderate ad spend increase in Asia/Europe/Latin America and share gains from Yahoo (YHOO)/Microsoft (MSFT). The analyst reiterates an Outperform rating and $970 price target on the shares.
10/21/16
10/21/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Yahoo (YHOO) downgraded to Hold from Buy at Jefferies with analyst Brian Fitzgerald citing valuation. 2. Skechers (SKX) downgraded to Neutral from Buy at Citi with analyst Corinna Van der Ghinst saying visibility over the next 12 months is "challenging." 3. Signature Bank (SBNY) downgraded to Market Perform from Outperform at BMO Capital with analyst Lana Chan saying the New York taxi portfolio is a lingering concern and a proactive reserve build or mark down would relieve an overhang. 4. Union Pacific (UNP) downgraded to Market Perform from Outperform at Cowen with analyst Walter Spracklin saying trends in pricing and margins are a concern and appear to be company specific. 5. Gastar Exploration (GST) downgraded to Market Perform from Outperform at FBR Capital analyst Chad Mabry citing valuation after the stock rallied 25%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VZ Verizon
$53.09

0.405 (0.77%)

01/03/17
SBSH
01/03/17
UPGRADE
Target $60
SBSH
Buy
Verizon upgraded to Buy from Neutral at Citi
Citi analyst Michael Rollins upgraded Verizon Communications to Buy and raised his price target for the shares to $60 from $55. The shares closed Friday down 36c to $53.38. The stock can reach $69 if everything were to go the company's way with respect to spectrum, tax reform, and its growth strategy for 5G, Rollins tells investors in a research note. He sees potential for valuation expansion citing Verizon's improving cash flow and expanding addressable market for revenue.
01/03/17
01/03/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Evercore ISI analyst Vijay Jayant upgraded Disney (DIS) to Buy from Hold, named it Top Pick for 2017, and raised its price target to $120 from $103. Jayan believes Disney's valuation reflects well-understood short-term growth challenges at ESPN and tough Studio and Consumer Products growth comparisons. 2. Wells Fargo analyst Marci Ryvicker upgraded 21st Century Fox (FOXA) to Outperform saying the market could be surprised by the synergies from the Sky deal. The analyst also believes concerns over the Regional Sports Networks being excluded from the streaming bundles are overblown. She expects consensus estimates to go up not down and raised her price target range for the shares to $33-$35 from $28-$30. 3. Citi analyst Michael Rollins upgraded Verizon (VZ) Communications to Buy from Neutral and raised his price target for the shares to $60 from $55. 4. Evercore ISI upgraded PACCAR (PCAR) to Buy from Hold and raised its price target to $77 from $59, with analyst David Raso saying he is incrementally bullish on the Industrials and Machinery sector since his pre-US election sector upgrade. 5. Credit Suisse upgraded Xerox (XRX) to Outperform from Neutral. Analyst Kulbinder Garcha changed his rating following the Conduent (CNDT) spin-off citing a more focused printing business, potential upside to cost savings, and management's realistic vision and a well laid out long-term strategy to offset end market decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/03/17
BTIG
01/03/17
NO CHANGE
BTIG
BTIG views Zayo as potential target for cable operators
An acquisition of Zayo Group (ZAYO) could extend the fiber footprint of cable operators like Comcast (CMCSA), BTIG analyst Walter Piecyk tells investors in a research note. He views Zayo's $13B enterprise value as "digestible" for the cable companies, but notes Verizon Communications (VZ) or Crown Castle (CCI) could be interested in a competitive bid should Zayo be "put in play." Shares of Zayo are up 16c to $33.02 in afternoon trading.
BABA Alibaba
$97.46

2.74 (2.89%)

12/08/16
12/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alibaba (BABA) coverage assumed with an Overweight at Morgan Stanley. 2. BioMarin (BMRN) initiated with a Buy at Gabelli. 3. Costco (COST) initiated with an Outperform at Credit Suisse. 4. Expedia (EXPE) initiated with an Outperform at CLSA while TripAdvisor (TRIP) was initiated with an Underperform. 5. Cree (CREE) initiated with an Outperform at JMP Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/28/16
EVER
12/28/16
NO CHANGE
EVER
Amazon, Alibaba named top Internet picks for 2017 at Evercore ISI
Evercore ISI Ken Sena looked ahead to what 2017 may likely bring in the Internet space, saying he believes scale in audience and infrastructure will continue to matter most. In that context, he called Amazon (AMZN) his top pick, seeing it as best positioned to leverage the growing data science trend. Alibaba (BABA), which he sees as a very attractive China ecommerce story with 440M active buyers, is another preferred recommendation, said Sena, who also listed Facebook (FB), Alphabet (GOOG), JD.com (JD), Priceline (PCLN) and Tencent (TCEHY) as additional buys in the coming year.
01/03/17
ROTH
01/03/17
NO CHANGE
Target $8.5
ROTH
Buy
Alibaba partnership further validates Remark Media KanKan, says Roth Capital
Roth Capital analyst Darren Aftahi says Remark Media's (MARK) partnership with Alibaba (BABA) Cloud for artificial intelligence further deepens its relationship with the latter. The analyst believes the opportunity is incremental to its credit scoring product with Alibaba and allows Remark Media addition monetization opportunities within Alibaba Cloud's ecosystem. While Aftahi expects P&L impact could be later in 2017, it gives him further confidence that his $5M KanKan 2017 revenue estimate could prove conservative. He reiterates a Buy rating and $8.50 on Remark Media's shares.
01/09/17
STPT
01/09/17
UPGRADE
Target $113
STPT
Accumulate
Alibaba upgraded to Accumulate from Hold at Standpoint Research
Price target $113.
VRX Valeant
$16.27

0.919 (5.99%)

01/10/17
BMOC
01/10/17
NO CHANGE
Target $21
BMOC
Market Perform
Valeant sales of Dendreon, CeraVe a 'good start,' says BMO Capital
BMO Capital analyst Gary Nachman said Valeant's (VRX) sales of Dendreon to Sanpower Group and CeraVe, AcneFree and AMBI to L'Oreal (LRLCY) for roughly $2.1B in cash have a combined average sales multiple of 4.4x, which appears to be a "solid price" and a good start for the company as it looks to sell additional assets to address its debt. Nachman also noted that Valeant announced that its second Phase 3 study for IDP-118 was successful, though he remains cautious on the drug given that most psoriasis creams are generic at this point. The analyst keeps a Market Perform rating and $21 price target on Valeant shares, which are up nearly 13% to $17.31 in pre-market trading.
01/10/17
WELS
01/10/17
NO CHANGE
WELS
Underperform
Valeant hiked prices on over 50 products last week, says Wells Fargo
Wells Fargo analyst David Maris said last night that on January 6, Valeant Pharmaceuticals implemented 95 different price increases across more than 50 products. This shows the company continues to rely on price as a means of growth and may also signal that Valeant's prescription volumes continue to remain challenged, Maris told investors in a research note. He reminds investors that Friday's price hikes "come on top of significant price increases--some of them more than 100%--taken on products in previous years and several taken in late 2016." Maris continues to believe the "new Valeant" is the "same Valeant using the same strategy and pricing levers that have been used before." The analyst keeps an Underperform rating on the shares with a $10-$13 price target range. The stock is up 12% to $17.20 in pre-market trading following the announcement of several asset sales.
01/10/17
01/10/17
NO CHANGE

Wells Fargo says Valeant debt problematic, base business still weak
Wells Fargo analyst David Maris said the proceeds announced today from Valeant's sale of its Dendreon unit, CeraVe and two other products would cover some, but not all, of the approximately $3.8B in debt the company has due in 2018. Valeant has not made clear in its press releases if these deals are dilutive to EPS, noted Maris, who believes the company's debt is problematic and base business remains weak. Maris keeps an Underperform rating on Valeant shares.
01/04/17
PIPR
01/04/17
NO CHANGE
Target $11
PIPR
Underweight
Piper calls Valeant 'not investable,' cuts target to $11
Piper Jaffray analyst David Amsellem cut his price target for Valeant Pharmaceuticals to $11 from $16 and reiterates an Underweight rating on the shares. The drugmaker closed yesterday up 72c to $15.24. After taking a closer look at prescription trends across the company's U.S. business, Amsellem believes shares of Valeant are "not investable." The company faces "significant pressure" from generic competition on high-margin assets while the "picture on the whole continues to look challenging," the analyst tells investors in a research note. He believes the likelihood of "significant pressure on the shares is far higher than that of potential recovery."
LRLCY L'Oreal
$36.22

0.395 (1.10%)

11/29/16
RBCM
11/29/16
UPGRADE
RBCM
Sector Perform
L'Oreal upgraded to Sector Perform from Underperform at RBC Capital
RBC Capital analyst James Edwardes Jones upgraded L'Oreal to Sector Perform with a price target of EUR 159.
09/09/16
BREN
09/09/16
INITIATION
BREN
Hold
L'Oreal initiated with a Hold at Berenberg
Price target EUR 172.
11/04/16
STFL
11/04/16
UPGRADE
STFL
Buy
L'Oreal upgraded to Buy from Hold at Stifel
Stifel analyst Mark Astrachan upgraded L'Oreal based on the acceleration of the company's sales growth in Q3. The analyst thinks that the acceleration indicates that the company is "gaining meaningful share" of the global beauty market, and he predicts that its sales will increase at least 4%-5% over the next two to three years.
11/29/16
RBCM
11/29/16
UPGRADE
RBCM
Sector Perform
L'Oreal upgraded on make-up performance, share buyback potential at RBC Capital
As noted earlier, RBC Capital upgraded L'Oreal (LRLCY) to Sector Perform from Underperform. Analyst James Edwards upgraded the stock partly due to what he calls "the outstanding performance" of the company's make-up business. Additionally, he believes that the company could launch a significant share buyback initiative if Nestle (NSRGY) new CEO chooses to sell that company's 23% stake in L'Oreal. Edwards says that such a scenario is "a very real prospect." Target to $159 from $150.
CUDA Barracuda
$24.36

0.59 (2.48%)

01/10/17
01/10/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Express (AXP) upgraded to Outperform from Perform at Oppenheimer with analyst Ben Chittenden citing a better economic backdrop and the stock's underperformance relative to peers since the U.S. election. 2. Barracuda (CUDA) was upgraded to Neutral from Underperform at DA Davidson and to Overweight from Equal Weight at Stephens. 3. Acuity Brands (AYI) was upgraded to Outperform from Neutral at Baird and to Buy from Outperform at CLSA. 4. E-Trade (ETFC) upgraded to Buy from Neutral at Goldman with analyst Conor Fitzgerald saying he expects revenue acceleration from higher rates combined with balance sheet growth from deposit sweeps, focus on expenses by new management, and potential for reduced bank regulation. 5. Time Inc. (TIME) upgraded to Outperform from Market Perform at Wells Fargo with analyst Eric Katz citing potential upside from a takeover by Meredith (MDP). A combination makes sense, and Meredith shares are pricing in a $23 purchase price for Time, Katz tells investors in a research note. Should a deal not materialize, Time shares could fall to $14, but it's more likely a deal is done at $23 per share, the analyst argues. Katz raised his price target range for Time to $21-$23 from $15-$17. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/17
BARD
01/10/17
NO CHANGE
Target $31
BARD
Outperform
Barracuda price target raised to $31 from $29 at Baird
Baird analyst Jayson Noland raised his price target on Barracuda to $31 from $29 following better than expected Q3 results. The analyst noted its solid guidance, strong core billings performance, and what appears to be the company's transition to a cloud-based model faster than most others across the IT landscape. Noland reiterated his Outperform rating on Barracuda shares.
01/10/17
01/10/17
UPGRADE
Target $30

Overweight
Barracuda upgraded to Overweight at Stephens
As previously reported, Stephens analyst Jonathan Ruykhaver upgraded Barracuda to Overweight from Equal Weight to reflect improved execution and positioning that is driving higher growth, after the company reported Q3 results that once again beat on revenue, earnings, and billings. The analyst believes the cloud security market is large and underserved to date, and believes Barracuda's early mover advantage and focus on delivering high security prevention at "very effective" price points positions the company well for success. He also raised his price target on the shares to $30 from $24.
01/10/17
SPHN
01/10/17
UPGRADE
SPHN
Overweight
Barracuda upgraded to Overweight from Equal Weight at Stephens
ILMN Illumina
$141.54

0.05 (0.04%)

01/10/17
BOFA
01/10/17
UPGRADE
Target $175
BOFA
Buy
Illumina upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Derik de Bruin upgraded Illumina to Buy and raised its price target to $175 from $145 following the announcement of a new sequencing platform, the NovaSeq. The analyst believes the NovaSeq is a substantial improvement over the current high-end sequencing platform, the HiSeq family, and will be a major new product cycle driving top-line acceleration and approximately 20% earnings growth in 2018.
01/10/17
LEER
01/10/17
NO CHANGE
Target $132
LEER
Market Perform
Illumina price target raised to $132 from $114 at Leerink
Leerink analyst Puneet Souda raised his price target for Illumina to $132 from $114 after the company announced Q4 sales, 2017 revenue and EPS guidance, and announced the launch of NovaSeq high-throughput sequencing platform. The analyst says that while he sees this instrument upgrade as "meaningful," Souda believes it will only deliver additional capacity into a market already experiencing overcapacity in the near-term. He reiterates a Market Perform on the shares.
01/06/17
KING
01/06/17
UPGRADE
KING
Buy
Illumina upgraded to Buy from Neutral at CL King
01/10/17
PIPR
01/10/17
NO CHANGE
Target $170
PIPR
Overweight
Illumina price target raised to $170 from $148 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Illumina to $170 saying the company's new high-throughput platform, NovaSeq, could "spawn a multi-year upgrade cycle." The shares typically perform well during upgrade cycles, Quirk tells investors in a research note. He keeps an Overweight rating on Illumina.
SRPT Sarepta
$31.26

1.18 (3.92%)

12/23/16
OPCO
12/23/16
NO CHANGE
Target $76
OPCO
Outperform
Oppenheimer remains bullish on Sarepta
Oppenheimer analyst Hartaj Singh notes that Sarepta has a commercial and active product in Exondys 51 for Exon 51 amenable Duchenne muscular dystrophy, a disease with a high unmet need. The analyst believes that a "complex reimbursement environment" coupled with a small target patient population in the U.S. could lead to a slower launch than expected. However, once the reimbursement process is settled and the patient on-boarding process is efficient, he expects a stronger sales ramp. Singh remains bullish on the stock, and reiterates an Outperform rating and $76 price target on the shares.
12/22/16
12/22/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Microsoft (MSFT) initiated with an Overweight at Piper Jaffray. 2. Sarepta (SRPT) initiated with an Overweight at JPMorgan. 3. Oracle (ORCL) initiated with an Overweight at MUFG. 4. Zillow (Z, ZG) initiated with a Hold at Stifel. 5. Las Vegas Sands (LVS) was initiated with a Buy and Wynn Resorts (WYNN) was initiated with a Neutral at Aegis. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/06/17
JMPS
01/06/17
NO CHANGE
Target $65
JMPS
Outperform
Sarepta price target lowered to $65 after physician survey at JMP Securities
JMP Securities analyst Liisa Bayko reported the firm conducted its first survey of U.S. physicians who treat Duchenne muscular dystrophy patients to gauge early experiences with Sarepta's Exondys 51. At the end of 2016, respondents had written a prescription to about 1 in 5 eligible patients, 1 in 5 were denied coverage and about 15% were in the adjudication process, noted Bayko, who lowered her price target on Sarepta to $65 from $90 to adjust for the survey results as well as an updated pricing analysis. Bayko keeps an Outperform rating on Sarepta and said she sees potential upside to about $160 per share if Exondys 51 is approved in the EU and if all of its earlier-stage assets targeting exons 45/53 are successful.
01/10/17
BARD
01/10/17
NO CHANGE
Target $102
BARD
Outperform
Baird expects Sarepta 'relief rally' on launch update
Baird analyst Brian Skorney expects a "relief rally" in shares of Sarepta Therapeutics after the company announced Exondys 51 sales of $5.4M and greater than 250 patient start forms were submitted by year-end. If the shares were at $60, the sales figure would be a disappointment, but expectations have been lowered and whisper numbers were nearing negative territory, Skorney tells investors in a research note following Sarepta's JPMorgan Conference presentation. "This is just the beginning," as the company has dystrophin data coming from SRP-4053 in exon-53-amenable patients in the first half of 2017 and data plans to advance at least three additional assets, the analyst contends. Skorney keeps an Outperform rating on Sarepta with a $102 price target.
DFRG Del Frisco's
$15.85

-0.15 (-0.94%)

11/29/16
FBCO
11/29/16
UPGRADE
FBCO
Outperform
Del Frisco's upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Jason West upgraded Del Frisco's to Outperform and raised its price target to $19 from $15 saying it is a key beneficiary of improved high-end consumer and corporate spending. West said Del Frisco's is the most effective way to gain exposure to several of Trump's stated priorities of individual and corporate tax reform, resulting in increased disposable income and revitalized business spending.
11/16/16
SPHN
11/16/16
DOWNGRADE
SPHN
Equal Weight
Del Frisco's downgraded to Equal Weight from Overweight at Stephens
08/22/16
ADAM
08/22/16
INITIATION
Target $16
ADAM
Hold
Del Frisco's initiated with a Hold at Canaccord
Canaccord analyst Lynne Collier initiated Del Frisco's with a Hold rating and $16 price target.
11/29/16
11/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying he sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders. 2. Comerica (CMA) upgraded to Outperform from Market Perform at Keefe Bruyette. 3. Tractor Supply (TSCO) upgraded to Buy from Neutral at Northcoast with analyst Chuck Cerankosky saying he expects the company to benefit from colder weather and the improving US economy and said product assortments and promotions have also been adjusted to the new economics of the energy patch and its impact on this company's customers. 4. Del Frisco's (DFRG) upgraded to Outperform from Neutral at Credit Suisse with analyst Jason West saying it is a key beneficiary of improved high-end consumer and corporate spending. 5. Veracyte upgraded to Buy from Neutral at Janney Capital with analyst Paul Knight saying the company's "disciplined test development, commercialization, and reimbursement processes" insulate it from a number of problems plaguing the pharma sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ASNA Ascena Retail
$6.01

0.01 (0.17%)

12/15/16
GSCO
12/15/16
INITIATION
Target $7
GSCO
Neutral
Ascena Retail initiated with a Neutral at Goldman
Goldman Sachs analyst Lindsay Drucker Mann started Ascena Retail with a Neutral rating and $7 price target.
09/20/16
09/20/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ford (F) downgraded to Neutral from Buy at Buckingham with analyst Joseph Amaturo saying he believes North American volume and pricing trends for trucks will deteriorate and is concerned that the passenger car market will remain challenged given stiff competition from Japanese and European OEMs that can heavily discount due to weak currencies. 2. General Mills (GIS) downgraded to Underperform from Neutral at Consumer Edge. 3. Ascena Retail (ASNA) downgraded to Sector Perform from Outperform at RBC Capital and to Perform from Outperform at Oppenheimer. 4. Avnet (AVT) downgraded to Hold from Buy at Stifel and to Sell from Hold at Cross Research. 5. HD Supply (HDS) downgraded to Sector Perform from Outperform at RBC Capital with analyst Deane Dray saying it will take several quarters for the company to address its supply chain errors, and she expects the stock "to stay range bound over the medium term." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/20/16
RHCO
09/20/16
NO CHANGE
RHCO
Ascena Retail outlook still positive despite Q4 miss, says SunTrust
SunTrust analyst Pamela Quintiliano says that Ascena's initiatives remain on track, as the momentum of its Justice unit should continue during the holiday season. She thinks that the company has multiple additional near-term positive catalysts. The analyst cut her price target on the shares to $8 from $10 but keeps a Buy rating on the stock.
09/20/16
RBCM
09/20/16
DOWNGRADE
RBCM
Sector Perform
Ascena Retail downgraded on Q4 results at RBC Capital
As noted earlier, RBC Capital downgraded Ascena to Sector Perform from Outperform. Analyst Brian Tunick downgraded the stock based on the company's Q4 EPS miss and its lower than expected fiscal 2017 EPS guidance. Target $7.
WMB Williams
$28.85

-3.085 (-9.66%)

01/10/17
BERN
01/10/17
NO CHANGE
BERN
Williams shares should be bought on weakness, says Bernstein
Bernstein analyst Jean Ann Salisbury was disappointed by Williams' (WMB) "financial repositioning" moves, as she wanted the company to continue carrying out the plan that it had announced in August. However, she notes that her free cash flow estimates for the company have not changed, and she says that its decision to eliminate its IDRs will result in greater simplicity. The analyst keeps a $35 price target and an Outperform rating on Williams and a $42 price target and an Outperform rating on Williams Partners (WPZ).
01/10/17
JEFF
01/10/17
DOWNGRADE
Target $32
JEFF
Hold
Williams downgraded to Hold from Buy at Jefferies
Jefferies analyst Christopher Sighinolfi downgraded Williams (WMB) to Hold saying Williams Partners (WPZ) is the greater beneficiary from the company's efforts to simply its corporate structure. The analyst lowered his price target for Williams to $32.
01/10/17
LEHM
01/10/17
DOWNGRADE
LEHM
Equal Weight
Williams downgraded to Equal Weight from Overweight at Barclays
12/19/16
12/19/16
UPGRADE
Target $35

Overweight
Williams upgraded to Overweight at Morgan Stanley
As previously reported, Morgan Stanley upgraded Williams (WMB) to Overweight from Equal Weight and raised its price target to $36 from $26. Analyst Tom Abrams said management has made progress stabilizing the company and is taking a "fresh loo" at the Williams/Williams Partners (WPZ) structure. He believes a consolidation transaction with Williams buying Williams Parters may be the preferred remedy and would reduce downside risk and improve free cash flow visibility.
WPZ Williams Partners
$38.64

-0.025 (-0.06%)

12/05/16
LEHM
12/05/16
INITIATION
Target $37
LEHM
Equal Weight
Williams Partners reinstated with an Equal Weight at Barclays
Barclays analyst Christine Cho reinstated coverage of Williams Partners with an Equal Weight rating and $37 price target.
01/10/17
STFL
01/10/17
UPGRADE
STFL
Buy
Williams Partners upgraded to Buy from Hold at Stifel
Stifel analyst Selman Akyol upgraded Williams Partners after the company's "financial repositioning" moves. The analyst thinks that the changes address his previous concerns about the company's high cost of capital. He believes that the moves leave the company well-positioned for "sustainable growth" going forward. Target to $43 from $37.
WDFC WD-40
$117.30

-1.95 (-1.64%)

08/25/16
08/25/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cree (CREE) initiated with a Buy at Roth Capital. 2. Reynolds American (RAI) initiated with a Neutral at UBS. 3. Twilio (TWLO) initiated with a Hold at Argus. 4. Phillips 66 Partners (PSXP) initiated with a Neutral at Goldman. 5. WD-40 (WDFC) initiated with a Hold at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/25/16
JEFF
08/25/16
INITIATION
Target $120
JEFF
Hold
WD-40 initiated with a Hold at Jefferies
Jefferies analyst Daniel Rizzo initiated WD-40 with a Hold rating and $120 price target, as he believes the stock's current valuation leaves the company "little margin for error."

TODAY'S FREE FLY STORIES

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

17:55
11/17/17
11/17
17:55
11/17/17
17:55
Hot Stocks
MKS Instruments to replace Brocade in S&P 400 at open on 11/22 »

S&P 500 constituent…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UQM

UQM Technologies

$1.18

0.015 (1.29%)

17:24
11/17/17
11/17
17:24
11/17/17
17:24
Syndicate
Breaking Syndicate news story on UQM Technologies »

UQM Technologies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$238.02

-1.35 (-0.56%)

17:23
11/17/17
11/17
17:23
11/17/17
17:23
Periodicals
Goldman Sachs has $510M lawsuit dismissed, Reuters reports »

A $510M lawsuit that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.94

-0.02 (-1.02%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Breaking Hot Stocks news story on Vical »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Ligand director sells 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CFO sells 6,559 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CEO sells 5,269 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$9.01

0.13 (1.46%)

17:15
11/17/17
11/17
17:15
11/17/17
17:15
Hot Stocks
Breaking Hot Stocks news story on MBIA »

Fine Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBCN

Rubicon

$8.07

0.1218 (1.53%)

17:03
11/17/17
11/17
17:03
11/17/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Rubicon »

Bandera Partners reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANCB

Anchor Bancorp

$24.75

-0.1 (-0.40%)

17:02
11/17/17
11/17
17:02
11/17/17
17:02
Hot Stocks
Anchor Bancorp announces stock repurchase program, 10b5-1 trading plan »

Anchor Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:58
11/17/17
11/17
16:58
11/17/17
16:58
Syndicate
Breaking Syndicate news story on Gulf Island Fabrication »

Gulf Island Fabrication…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$31.09

0.59 (1.93%)

16:51
11/17/17
11/17
16:51
11/17/17
16:51
Hot Stocks
Mid Penn Bancorp, Scottdale shareholders approve merger »

Mid Penn Bancorp and The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CALD

Callidus Software

$28.95

0.3 (1.05%)

16:49
11/17/17
11/17
16:49
11/17/17
16:49
Initiation
Callidus Software initiated at First Analysis »

Callidus Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:46
11/17/17
11/17
16:46
11/17/17
16:46
Hot Stocks
Breaking Hot Stocks news story on Gulf Island Fabrication »

Piton Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

16:42
11/17/17
11/17
16:42
11/17/17
16:42
Hot Stocks
General Electric CEO acquires 60,000 common shares »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRE

Northstar Realty Europe

$14.20

0.05 (0.35%)

16:33
11/17/17
11/17
16:33
11/17/17
16:33
Syndicate
Breaking Syndicate news story on Northstar Realty Europe »

Northstar Realty Europe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

FHN

First Horizon

$18.40

0.1 (0.55%)

, CBF

Capital Bank

$39.95

0.25 (0.63%)

16:33
11/17/17
11/17
16:33
11/17/17
16:33
Hot Stocks
First Horizon, Capital Bank agree to sell two branches to Apex Bank »

First Horizon (FHN) and…

FHN

First Horizon

$18.40

0.1 (0.55%)

CBF

Capital Bank

$39.95

0.25 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$194.25

-0.75 (-0.38%)

16:32
11/17/17
11/17
16:32
11/17/17
16:32
Hot Stocks
Lennox executive sells 2,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

TBNK

Territorial Bancorp

$30.99

0.21 (0.68%)

16:31
11/17/17
11/17
16:31
11/17/17
16:31
Hot Stocks
Territorial Bancorp declares special cash dividend of 30c per share »

Payable on December 20.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRTN

Triton International

$40.07

-0.77 (-1.89%)

16:30
11/17/17
11/17
16:30
11/17/17
16:30
Hot Stocks
Triton International's Hanau sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
11/17/17
11/17
16:30
11/17/17
16:30
Options
Preliminary option volume of 21.1M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.